ATRA Atara Biotherapeutics, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1604464 · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY1,404.0%
TTM net income YoY69.1%
TTM EPS YoY82.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-64.7%
Net margin-66.2%
FCF margin-53.5%
EBITDA margin-61.8%
Returns
ROE-8,768.3%
ROA-62.2%
ROIC (approx.)—
Asset turnover0.94x
Leverage & solvency
Liabilities / assets189.2%
Debt / equity—
Current ratio0.48x
Interest coverage-18.08x
Cash quality & payout
Operating cash flow / net income0.80x
Accruals ratio-12.2%
Payout ratio—
Capex / revenue0.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $120.77M | $128.94M |
| R&D expense | $37.45M | $151.48M |
| SG&A expense | $26.25M | $39.89M |
| Operating income | $35.86M | -$83.44M |
| Interest expense | $3.79M | $4.62M |
| Pretax income | $32.72M | -$85.42M |
| Income tax | $31,000 | -$12,000 |
| Net income | $32.69M | -$85.40M |
| EBITDA | $37.98M | -$78.39M |
| EPS (basic) | 2.61 | -11.41 |
| EPS (diluted) | 2.57 | -11.41 |
| Weighted avg. shares (diluted) | 12.72M | 7.49M |
| Balance sheet | ||
| Cash & equivalents | $8.48M | $25.18M |
| Short-term investments | $0 | $17.47M |
| Receivables | $1.25M | $1.48M |
| Inventory | $0 | $10.65M |
| Current assets | $12.21M | $64.89M |
| PP&E, net | $73,000 | $1.29M |
| Total assets | $20.23M | $109.10M |
| Current liabilities | $14.92M | $134.57M |
| Total liabilities | $58.74M | $206.38M |
| Shareholders' equity | -$38.50M | -$97.28M |
| Shares outstanding | 7.32M | 5.86M |
| Cash flow statement | ||
| Operating cash flow | -$50.94M | -$68.72M |
| Capital expenditure | $0 | $246,000 |
| Free cash flow | -$50.94M | -$68.96M |
| Investing cash flow | $18.15M | $8.62M |
| Financing cash flow | $16.10M | $59.28M |
| Depreciation & amortization | $2.12M | $5.05M |
| Stock-based compensation | $9.75M | $27.00M |
Free plan shows the latest 2 periods; Pro shows all 14 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.